We are open to partnering, contact our team at
A delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases
Metabolic Diseases – A Fast Growing Market
GLP-1R Agonist market expected to exceed $150bn by 2031
Worldwide obesity has nearly tripled since 1975 & obesity treatment could quickly become a top-12 global therapy
Proof-of-technology clinical trial preparation underway
Trial to determine that a Glucagon-like Peptide 1 receptor (GLP-1R) agonist can be delivered orally in humans expected to commence in H1 2024
The effectiveness of the technology in successfully delivering APIs across the gut wall and eliciting the required biological response / clinical benefit has been demonstrated in small scale Proof of Concept human clinical trials.
In December 2022, we acquired an exclusive license to InsuCaps’ (sister company of AnaBio Technologies) oral delivery technologies for treating metabolic conditions such as obesity, pre-diabetes and diabetes. Obesity alone costs the US healthcare system c. $173bn a year.
Oral Delivery solves many problems
The Challenge
Potential benefits of applying our patented technology
Overcoming challenges
- Adaptable technology to tailor release in specific gut regions
- Natural biodegradability using a food-grade encapsulation platform
Mass access to treatment
- Easier to administer than an injection
- Reduced need for trained staff
- No needle phobia or biohazard waste
- People are more willing to take an oral product
Manufacturing & distribution
- Often easier to produce
- Superior thermostability
- Reduced need for cold chain
- Longer shelf life
- Easier distribution
